Understanding engraftment syndrome after stem cell transplant
Part of Blood & lymphatic clinical trials.
This study follows patients who develop engraftment syndrome—a treatable condition that can happen after a stem cell transplant—to better understand different types and improve outcomes. Researchers will track your recovery, complications, and long-term health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received or are scheduled to receive an allogeneic stem cell transplant (donor cells) at this hospital
- You developed engraftment syndrome after your transplant (a condition with fever, rash, and organ symptoms)
- Your doctors have medical records and lab results documenting your engraftment syndrome
- You can attend follow-up visits and allow researchers to review your medical information for at least several months after transplant
- You are willing to give written permission to participate in this research study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well patients do after receiving a stem cell transplant from a donor (called an allogeneic transplant). It aims to better understand the long-term outcomes and help improve care for future patients.
This study tracks patients who have had or are planning to have a stem cell transplant. It helps doctors learn more about long-term outcomes and improve care for future patients.
This study follows patients who have received a stem cell transplant from a donor to track and understand fungal infections that can occur afterward. By studying this carefully, researchers hope to better prevent and treat these serious infections in future patients.
This study looks at heart problems that can happen after a stem cell transplant from a donor (allogeneic). It aims to understand these risks better so doctors can help patients stay healthier after transplant.
This study uses a special score (immune risk score) to check how well your immune system rebuilds after a half-matched stem cell transplant. The goal is to find patients who might need extra help with immune recovery.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
Hear when a new Engraftment Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.